Dr. Deborah M. Stephens, D.O.
Hematology (Hematology (Internal Medicine) Physician)
2000 Circle Of Hope Dr
Salt Lake City, UT 84112
Who else practices at this address →
Salt Lake County includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Kansas City University of Med & Biosciences, College of Osteo Med (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 54
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: Kansas City University of Med & Biosciences, College of Osteo Med
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
NC license 2023-02724 · OH license 34.009815 -
Hematology & Oncology Physician
UT license 9030731-1204
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Unc Hospitals Chapel Hill, NC
Medical groups
- University of North Carolina at Chapel Hill (2,052 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 54
- Services billed
- 235
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 92 | 73 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 64 | 15 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 18 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Calquence (acalabrutinib maleate) | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 29 payments worth $14,870 in total to this clinician.
| Genentech USA, Inc. | $3,629 |
|---|---|
| Lilly USA, LLC | $3,200 |
| Beone Medicines USA, Inc. | $3,020 |
| Beigene USA, Inc. | $2,400 |
| AbbVie Inc. | $1,598 |
| Janssen Biotech, Inc. | $798 |
| AstraZeneca Pharmaceuticals LP | $161 |
| Syndax Pharmaceuticals, Inc. | $64.73 |
| Consulting Fee | $12,710 |
|---|---|
| Food and Beverage | $1,239 |
| Travel and Lodging | $878 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Feb 18, 2025 | Consulting Fee JAYPIRCA · Oncology | $3,200 |
| Genentech USA, Inc. May 30, 2025 | Consulting Fee Rituxan; Polivy; Venclexta · BioOncology/Immunology | $2,460 |
| Beone Medicines USA, Inc. Aug 19, 2025 | Consulting Fee BRUKINSA · Oncology | $2,400 |
| Beigene USA, Inc. Mar 7, 2025 | Consulting Fee BRUKINSA · Oncology | $2,400 |
| Janssen Biotech, Inc. Dec 19, 2025 | Consulting Fee IMBRUVICA · Oncology | $750 |
| Genentech USA, Inc. May 30, 2025 | Travel and Lodging Rituxan; Polivy; Venclexta · BioOncology/Immunology · travel to Chicago, IL · in-kind | $413 |
| Genentech USA, Inc. May 30, 2025 | Travel and Lodging Rituxan; Polivy; Venclexta · BioOncology/Immunology · travel to Chicago, IL · in-kind | $381 |
| AbbVie Inc. Jan 8, 2025 | Consulting Fee IMBRUVICA · ONCOLOGY | $375 |
| AbbVie Inc. Mar 11, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $375 |
| AbbVie Inc. May 28, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $375 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 19, 2025 | Consulting Fee IMBRUVICA · Oncology | $750 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
| AbbVie Inc. Oct 24, 2025 | Consulting Fee IMBRUVICA · ONCOLOGY | $375 |
| Beone Medicines USA, Inc. Aug 19, 2025 | Consulting Fee BRUKINSA · Oncology | $2,400 |
| Genentech USA, Inc. May 30, 2025 | Consulting Fee Rituxan; Polivy; Venclexta · BioOncology/Immunology | $2,460 |
| Genentech USA, Inc. May 30, 2025 | Travel and Lodging Rituxan; Polivy; Venclexta · BioOncology/Immunology · travel to Chicago, IL · in-kind | $413 |
| Genentech USA, Inc. May 30, 2025 | Travel and Lodging Rituxan; Polivy; Venclexta · BioOncology/Immunology · travel to Chicago, IL · in-kind | $381 |
| Genentech USA, Inc. May 30, 2025 | Travel and Lodging Rituxan; Polivy; Venclexta · BioOncology/Immunology · travel to Chicago, IL | $83.99 |
| AbbVie Inc. May 28, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $375 |
| AbbVie Inc. Mar 11, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $375 |
| Beigene USA, Inc. Mar 7, 2025 | Consulting Fee BRUKINSA · Oncology | $2,400 |
| Lilly USA, LLC Feb 18, 2025 | Consulting Fee JAYPIRCA · Oncology | $3,200 |
| AbbVie Inc. Jan 8, 2025 | Consulting Fee IMBRUVICA · ONCOLOGY | $375 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $764,910 in research payments for these studies, mostly to the institutions running them.
- Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Beigene, Ltd. · Active, not recruiting · NCT06073821 - Randomized Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.